Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 16, 2015; 3(7): 599-606
Published online Jul 16, 2015. doi: 10.12998/wjcc.v3.i7.599
Epidemiology, management, and economic evaluation of screening of gallstone disease among type 2 diabetics: A systematic review
Lujie Chen, Yu-Ting Peng, Fu-Li Chen, Tao-Hsin Tung
Lujie Chen, Yu-Ting Peng, Fu-Li Chen, Tao-Hsin Tung, Faculty of Public Health, College of Medicine, Fu-Jen Catholic University, Taipei 24205, Taiwan
Tao-Hsin Tung, Department of Medical Research and Education, Cheng-Hsin General Hospital, Taipei 112, Taiwan
Author contributions: Chen L and Tung TH drafted the manuscript; Peng YT and Chen FL coordinated drafting the manuscript; all authors read and approved the final version of the manuscript.
Conflict-of-interest statement: We certify that all affiliations with or financial involvement in, within the past 5 years and foreseeable future, any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript are completely disclosed (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, royalties).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Tao-Hsin Tung, Department of Medical Research and Education, Cheng-Hsin General Hospital, Shih-Pai, Taipei 112, Taiwan. ch2876@chgh.org.tw
Telephone: +886-2-28264400-7704Fax: +886-2-28264550
Received: October 27, 2014
Peer-review started: October 29, 2014
First decision: December 12, 2014
Revised: March 10, 2015
Accepted: April 10, 2015
Article in press: April 14, 2015
Published online: July 16, 2015

Abstract

The knowledge of gallstone disease (GSD) is crucial to manage this condition when organizing screening and preventive strategies and identifying the appropriated clinical therapies. Although cholecystectomy still be the gold standard treatment for patients with symptomatic GSD, expectant management could be viewed as a valid therapeutic method for this disorder. If early treatment of GSD decreases the morbidity or avoids further cholecystectomy, it may save clinical care costs in later disease periods sufficiently to offset the screening and early treatment costs. In addition, whether routine screening for GSD is worthwhile depends on whether patients are willing to pay the ultrasonography screening cost that would reduce the risk of cholecystectomy. In this review we discuss the epidemiology, management, and economic evaluation of screening of GSD among type 2 diabetics.

Key Words: Gallstone disease, Epidemiology, Management, Economic evaluation, Type 2 diabetes

Core tip: According to the willingness-to-pay viewpoint, this review indicated that from the societal perspective but not from consumer viewpoint, it is worthwhile to organize a routine ultrasonography screening for gallstone disease in diabetic population for further cholecystectomy prevention.



INTRODUCTION

Gallstone disease (GSD) is a common gastrointestinal condition with crystalline deposits in the gallbladder and impaired excretion of bile into the intestine throughout the world[1]. GSD yields a relative lower mortality rate, however, a relative higher risk of mortality in GSD patients is not totally explained by the high mortality rate of related cancer. This high morbidity of GSD substantially affects the economy and public health[2]. The increasing incidence of GSD over the past several decades is due to parallel modifications in personal dietary habits and physical activity associated with the Western lifestyle[3]. In the absence of an organized screening program for symptomatic GSD, treating GSD and related complications yields substantial medical burden[1].

Based on the Wilson criteria, GSD is needed to screen due to it is one of essential health issues; the disease natural course should be known; there should be a recognizable latent or early symptomatic state; a screening process is easy to do and interpret, accurate, acceptable, reliable, and has good sensitivity and specificity; there should be an acceptable treatment recognized for this disorder; treatment is much better if began early; there should be a clinical policy on who should be treated; both diagnosis and treatment have good efficacy; and this condition should be a continuous disease process[4]. Both obesity and the metabolic syndrome have been viewed as risk factors related to GSD formation[3,5,6]. Epidemiologic evidence suggested that people with diabetes mellitus were at higher risk of stone formation[3,7]. Academic studies indicated an increased morbidity of GSD in diabetic patients[7-9]. In addition, hypertriglyceridemia, hyperinsulinemia, and autonomic neuropathy (leading to gallbladder hypomotility and biliary stasis) were also revealed as associated factors to the incident GSD diabetic population[7,8]. This implies that GSD formation and diabetes development may share pathophysiologic pathways[3]. However, how diabetes predisposes to GSD is still not well known[8].

The choice of ultrasound scanning in GSD evaluation is ideal as it is cheap, non-invasive, safe, and repeatable without known adverse effect on the patients in clinical scenarios[10]. For symptomatic GSD subjects, expectant management may also indicate a valid clinical therapy although cholecystectomy still represents the gold standard[11]. From the viewpoint of preventive medicine, early detection of GSD by routine ultrasonography screening followed by appropriate therapy could avoid the further cholecystectomy. This review aims to explore the epidemiology, management, and economic evaluation of screening of GSD among type 2 diabetics.

THE CLINICAL DIAGNOSIS OF GSD

It is often a diagnostic challenge to determine which abdominal symptoms are related to GSD. Typically, GSD pain occurs in the right upper quadrant of the abdomen, but pain is not specific in this area[12]. Fewer than 50% of those with GSD actually have clinical symptoms, and fewer than 10% further develop potentially life-threatening complications[13]. The physicians must depend on the patient’s description of the pain and results of laboratory examinations and diagnostic imaging to decide a appropriate diagnosis[12]. The physical examination also may show mild epigastric or right upper quadrant tenderness, but most patients do not have significant physical characteristics[13]. The majority of asymptomatic GSD will remain asymptomatic for a long time period.

Mechanisms underlying GSD formation include supersaturation of bile with cholesterol, consequent sedimentation, crystallization, and stone formation and abnormal gallbladder motor function with resultant delayed emptying and stasis of bile[10]. The availability of ultrasonography as viewed a valid tool for GSD diagnosis has allowed the evaluation of GSD morbidity[2]. It is safe, fast, and not expensive and involves no radiation exposure[13]. Positive findings include single or multiple stones, a positive Murphy sign on contact with the ultrasonographic probe, thickening of the gallbladder wall, and pericholecystic fluid[14]. Patients are usually left feeling unwell for as much as one or two days. If obstruction persists, it worsens movement and palpation, is associated with fever, and is localized to the right upper guardant part of abdomen, with the pain becoming sharp, which will result in acute cholecystitis[12,15]. Clinical studies showed higher positive (0.99-1.00) and negative (0.90-0.96) predictive values regarding the diagnostic efficacy, indicating that ultrasonography is a reliable technology for GSD screening[1,16]. However, a drawback is that its accuracy is dependent on the people who perform and interpret it[13].

Biliary pain occurs when the neck of the gallbladder is hindered by a gallbladder or stone pressure rises, producing a visceral foregut pain[15]. Factors that relate to choledocholithiasis include tests of abnormal liver function, common bile duct dilation of eight mm or more, and common bile duct stones identified by ultrasonography[17]. In addition, the abdominal plain radiography or computer tomography (CT) scan should also exclude the presence of calcified stones[18-20].

THE MORBIDITY OF GSD

Epidemiological studies in both Eastern and Western countries showed that ultrasonography is an reliable diagnostic tool for GSD morbidity[2,21-23]. The mechanisms of GSD have been implicated in type 2 diabetes. Some controversy exists regarding the association between diabetes and GSD, although population-based epidemiologic studies have demonstrated a positive relationship between type 2 diabetes and increased morbidity of GSD[1,24-26]. The possible pathogenic mechanism for this is that type 2 diabetic population with GSD may cause acute cholecystitis more obvious and make higher likelihood of progression to septicemia compared with non-diabetic subjects, who exhibit functioning gallbladders normally. Type 2 diabetic patients may show a higher lithogenic bile index compared with non-diabetics after adjustment for sex and age[9]. The association between type 2 diabetes and GSD is stronger among patients who have a history of treated diabetes mellitus than it is among those with a single disease history of diabetes, that is, hyperglycemia may affect gallbladder motility[21]. The linkage between obesity, diabetes, and GSD most likely originate from metabolic syndrome[16,27]. In addition, diabetic patients represent cases of hyperglycemia that reflect relevant effects on gallbladder motility[9].

Tables 1 and 2 indicate that many evidence-based studies of the prevalence, incidence, and risk factors for GSD have been conducted. However, it is difficult to appropriately compare the results of some studies because the heterogeneous nature of these studies (for example, patient selection), which varied significantly. The prevalence of overall GSD was higher than the general Chinese population in Taiwan when using the same methodology of GSD assessment[8,42]. Previous population based studies had resulted in disparate findings on diabetes mellitus and GSD[24,25]. In Italy, the estimated prevalence of GSD is significantly higher in diabetic patients than in the general population (24.8% vs 13.8%)[43]. In New Zealand, the prevalence of GSD in diabetics was estimated to be 32.7% as compared to 20.8% in the control group[44]. An epidemiological study in Nigeria concluded that 17.5% of the diabetic patients had GSD on ultrasound[10]. The study about the prevalence of GSD in Chinese type 2 diabetics is rare or lack of appropriate statistical methods. The overall prevalence of GSD among type 2 diabetics in Kinmen was 14.4%, including single stone 8.0%, multiple stones 3.2%, and cholecystectomy 3.2%[42]. Further, the overall prevalence among elderly type 2 diabetics was 17.1% (men: 14.5%, women: 19.0%), which included the presence of single stone, 9.1%; multiple stones, 4.4%; and cholecystectomy 3.7%[45]. Upon international comparison, the prevalence of any type of GSD falls within the range of 10%-32% in type 2 diabetics and is higher than that in non-diabetic patients[44,46-49].

Table 1 Prevalence of gallstone disease in various populations.
Ref.Study yearScreened numberSettingPrevalence ofgallstone diseaseAssociated factors
Elmehdaw et al[8]2009327Benghazi, LibyaDM: 9.75% Non-DM: 17.5%Age, obesity
Pradhan et al[28]200980NepalNon-vegetarian
Acalovschi et al[29]20091332Romania19% with chronic hepatitis C; 17% controlsAbdominal obesity, steatosis
Khan et al[30]20099175 (5050 males, 4125 females)EnglandMale fell from 20.2% to 19.1%, females fell from 30.4% to 29.0%Diabetes, not for CHD, BMI to females, elderly
Friedrich et al[31]20099206 (5559 from Danish, 3647 of German)Denmark, Northeast GermanyHigher BMI, unfavorable lipid levels, higher prevalence of diabetes
Walcher et al[32]20102147Germany8%Protective effect: alcohol consumption
Ruhl et al[33]201114228United States7.10%Cardiovascular disease, cancer
Al-Bayati et al[34]2012200Iraqi33% of diabetics, 17% of non-diabeticsBMI > 25 kg/m2, increased duration of DM, increased HbA1C, multiparous females
Jiang et al[35]20131270Shanghai, ChinaCAD (+): 19.5% CAD (-): 11.3%CAD
Agunloye et al[10]2013400Ibadan, Nigeria17.5%Age, BMI, DM, duration of the disease
Yilmaz et al[36]2014441Turkey12.2%Age, BMI, Gender, metabolic syndrome
Shen et al[37]20146511Taiwan13.2%Age, Gender, metabolic syndrome
Ibitoye et al[38]20141283Nigerian2.9%
Table 2 Incidence of gallstone disease in various populations.
Ref.Study yearScreened numberSettingIncidence of gallstoneAssociated factors
Festi et al[2]20089611Italy0.67% (0.66% in males, 0.81% in females)Risk factors: In men: increasing age, high BMI, history of diabetes, peptic ulcer and angina, and low cholesterol and high triglyceride levels; In females: increasing age and high BMI Predictors: In men: increasing age and pain in the right hypochondrium In females: increasing age
Halldestam et al[39]2009621Sweden1.39 per 100 person-yearsLength of follow-up and LDL-cholesterol levels Inversely: alcohol consumption
Jonas et al[40]20108901SwedenSurgical group: 122.2/10000 person-years controls: 22.2/10000 person-yearsAfter antiobesity surgery (A fivefold increased risk)
Liu et al[25]2012108850 (60734 diabetic patients and 48116 control patients)Taiwan0.632% per yearRisk factor: increased age Associated: high body mass index, elevated fasting plasma glucose levels, and nonalcoholic fatty liver disease
Chen et al[1]20141296Taiwan0.632%High body mass index, elevated fasting plasma glucose levels, nonalcoholic fatty liver disease
Heida et al[41]2014288Dutch5.9%BMI

Cross-sectional study designs only reveal useful information of disease prevalence, but reveal nothing about the incidence or temporality in the study population. To explore the incidence and causal relationships between predictive factors and disease, the population needs to be re-examined regarding follow-up time. The morbidity of GSD increases as age increases, noticeably elevating in people aged 40 years and older and becoming from 4- to 10-fold more likely[4,16]. The incidence of GSD appears to vary among test diabetic populations and differs among studies conducted in disparate countries[1]. In the general and elderly Chinese type 2 diabetes population, the incidence of GSD was 3.56% per year (95%CI: 1.78%-6.24% per year) and 4.17% per year (95%CI: 2.22%-7.05% per year), respectively[9,26]. Previous epidemiologic studies showed that the annual incidence of overall GSD in type 2 diabetics was higher than that in other general population-based studies[9,22]. In addition, evidence-based studies exploring GSD in the elderly sub-population have focused almost entirely on the consequences of interventions such as percutaneous cholecystostomy and endoscopic retrograde cholangiopancreatography, or on the management of elderly patients with symptomatic biliary disease at hospitals[50,51]. The annual incidence of GSD in elderly type 2 diabetics was also higher than that in younger diabetic patients or the general population using the same methodology of GSD assessments[2,26]. To explore the incidence and risk factors for GSD is essential to prevent its development and avoid the further cholecystectomy caused by complications, which is often insidious in nature.

Gallstone formation is multifactorial, and involves constitutional and environmental factors. People with GSD have increased mortality, overall mortality, and mortality from cardiovascular disease and cancer. This relationship exists for ultrasound diagnosed GSD and cholecystectomy[33]. GSD with complications, especially cholecystitis and cholangitis, in the elderly is related to higher morbidity and mortality rates[52].

THE NATURAL COURSE OF GSD

The natural course of GSD is usually not malignant, but complications contribute substantially to medical care costs and may even be life threatening[40]. One of the essential advantages of early detection of GSD is that ultrasonography could diagnose asymptomatic stages, which incurs early treatment and the prevention of major complications such as acute pancreatitis or gallbladder cancer[53,54]. The increasing magnitude and epidemiologic shifts in the natural history of GSD worldwide qualify for the need of research in different geographical areas, and also to explore the predictive factors[55,56]. This is particularly because the majority of risk factors associated with GSD are potentially modifiable[41]. In addition, cholecystectomy could be used to treat GSD, that is, the estimated utility value in subjects with GSD will be a 0.09 increase from this therapy. Thus, the number of quality-adjusted life years obtained from cholecystectomy would be 1.8 (0.09 × 20) if subjects had a life expectancy of 20 years[57]. Screening regimes for GSD depend on the incidence and progression rates as well as the risk factors that change these rates. An understanding of the disease progression of GSD would appropriately determine the benefits of prevention strategies.

A chronic disease model according to the epidemiologic information of GSD is necessary to allow the benefits of intervention to be modeled. Since GSD may only persist a short duration before cholecystectomy, a shorter desirable interscreening interval may be warranted. The disease progression of GSD affects the decision of a screening interval for the surveillance of this patient population. In addition, the effectiveness of screening strategy for GSD is determined by the progression of GSD[58]. Since the natural history of GSD may not be homogeneous across study countries, assumptions of disease progression parameters could not be directly compared from previous results[11,59]. Several evidence-based studies on the natural history of GSD also have been conducted[11,58]. A clearer understanding of the risk factors associated with GSD may help us to identify cases and to reduce the risk in some patients[60].

For the disease natural course of GSD, the four-state Markov chains model following the pathway of proliferative phase is showed as follows:

Math 1

Math 1
Math 1 Math(A1).

To estimate the progression rates, let λ12, λ23, and λ34 indicate the annual progression rate from state 1 to state 2, from state 2 to state 3, and from state 3 to state 4, respectively. The annual progression rates from single stone to multiple stones and from multiple stones to cholecystectomy are estimated as 0.114 (95%CI: 0.015-0.173) and 0.148 (95%CI: 0.101-0.242), respectively. Corresponding average durations in single stone state and multiple stones stage are 8.77 (95%CI: 5.78-66.67) years and 6.76 (95%CI: 4.13-9.90) years, respectively. The application of parameters to the annual transition probabilities from single stone state to multiple stones state and from multiple stones state to cholecystectomy state are 10.00% and 13.76%, respectively. An annual screening program could reduce cholecystectomy by 82.9% (95%CI: 75.7%-90.4%) compared with the non-screening group. Comparatively, biennial screening, 3-year screening, 4-year screening, and 5-year screening could reduce cholecystectomy by 71.6% (95%CI: 57.0%-88.8%), 64.8% (95%CI: 46.1%-81.5%), 49.6% (95%CI: 23.9%-75.3%), and 32.1% (95%CI: -2.8%-66.7%), respectively[58]. However, one problem is in four-state Markov chains model, we should be aware that single stone might not always consequentially develop into multiple stone.

Many factors such as obesity and type 2 diabetes have been indicated to be significant risk factors related to GSD[1,9,11], and the transition state is probably unstable over time. The screening efficacy of preventing cholecystectomy associated with GSD depends on early diagnosis. To choose the frequency of sonographic check-ups as well as sensitivity and specificity, it is helpful to know the disease scenario and progression from the asymptomatic state to the symptomatic state. This characteristic will provide early diagnosis and therapeutic strategies for GSD[57].

THE MANAGEMENT OF GSD

The treatment options for GSD are according to few crucial steps such as typical symptoms, further complications, and gallbladder function, as well as size and composition of GSD[18]. Cholecystectomy remains the reliable operation for patients with symptomatic GSD. It is safe because the lowest risk of recurrence and more than 90% of patients with complete biliary pain relief[12]. Currently, it is also under argumentation if cholecystectomy may be also used for pre-symptomatic GSD. It is generally presumed that surgical procedures are not suggested routinely in symptom-free subjects due to the low rate of complications[18].

Statins used could relieve hepatic cholesterol biosynthesis and may reduce biliary cholesterol secretion, consequently causing decreased cholesterol concentration in bile[61]. A larger observational study showed academic evidence that long-term use of statins is related to a decreased rate of diagnosed GSD requiring advanced cholecystectomy[62]. Another population-based case-control study also indicated that long-term sustained statin use decreases incident GSD in both men and women[63]. The results may be one of clinical relevancies given that GSD represents a major burden for medical care systems[62]. In addition, a previous study showed that ezetimibe could not only prevent cholesterol GSD through obstructing intestinal cholesterol absorption so that biliary cholesterol secretion is decreased, and gallbladder motility function is reserved by desaturating bile in gallstone-susceptible C57L mice disputed to the lithogenic diet, but also promote the dissolution of cholesterol GSD through a greater capacity to develop an abundance of unsaturated micelles[64]. For both prevention and treatment of cholesterol GSD, ezetimibe is viewed as a novel and potential cholelitholytic agent[65].

Oral bile acids have successfully dissolved GSD in an extremely limited patient population for the nonsurgical treatment of GSD[12]. The clinical effectiveness of bile acid therapy was determined in symptomatic GSD smaller than 15 mm within a functioning gallbladder[12]. Oral bile acids could be only selected in symptomatic GSD patients who are unsuitable for cholecystectomy and have small, uncalcified, and cholesterol-enriched stones with a patent cystic duct in a functioning gallbladder[18,66]. Currently, bile acid therapy is revealed only for patients unsuitable or unwilling to receive cholecystectomy[12,67].

A previous study showed that acute cholecystitis grows in up to 10% of symptomatic GSD patients and leads to the entire obstruction of the cystic duct[68]. Once acute cholecystitis is found, patients should be revived with intravenous fluids, accompanying medical conditions should be stabilized, and surgery should be performed at the earliest time[12]. In addition, GSD could migrate from their primary site in the gallbladder through the cystic duct and into the common bile duct[12]. An essential treatment for choledocholithiasis includes gallbladder removal and clearance of retained common bile duct stones. The findings of a prospective, multi-center, randomized controlled trial comparing single-stage laparoscopic cholecystectomy (LC) and laparoscopic stone extraction with preoperative endoscopic retrograde cholangiopancreatography followed by LC indicated that the procedures were equally effective in the clearance of common bile duct stones[69].

THE ECONOMIC EVALUATION OF SCREENING OF GSD

Based on the welfare economic theory, the maximum value of individual’s willingness-to-pay (WTP) is defined as the benefit to an individual receiving medical service or intervention[70]. For the WTP perspective, the payment vehicle not only refers to the means of payment by a patient, but also is assumed as total cost of both copayment for health insurance scheme and out-of-pocket money which is not covered by health insurance benefit[71]. An evidenced-based study indicated that 24.4% of subjects would not like to pay a screening cost for GSD detection, implying that they did not think GSD status would influence their daily quality of life. The WTP values were significantly higher in individuals with more advanced GSD than in those with mild GSD. This also suggests that GSD associates with impaired quality of life and thus such patients would pay more to reduce the sequelae of further cholecystectomy[70].

Economic evaluations are criticized commonly by decision makers for ignoring budget impacts, about which decision makers are desperately concerned. Payers could get into financial difficulty if they adopt too many cost-effectiveness interventions and affordability, which depends on the overall volume of patients, is therefore a prime concern[11,72]. Few well-organized population-based studies have been conducted to explore the cost and effectiveness of GSD screening regimes. The cost-benefit analysis was used in one study to discuss whether a GSD screening regime compared with non-screening group is worthwhile in Taiwan from different viewpoint. The findings revealed that indirect costs play a main role in the routine GSD screening regime. Annual screening program could save the most discounted indirect costs per case (NTD220345) (US$6995.1; 31.0NTD = 1USD) compared with non-screening group. Based on the health care payer’s viewpoint, annual screening discounted net cost was NTD24893 (US$790.3) per case. This implied that from health care payer’s viewpoint, the clinical efficacy from the routine annual screening regime could not exceed the cost incurred in the GSD screening strategy. To consider the indirect cost, the NTD245238 (US$7785.3) net saving per case indicates that from the societal perspective, the annual screening program is rather constructive (P < 0.0001)[72]. In Chile, a screening program for GSD in a high risk sub-population reveals significant cost-effectiveness. The incremental cost-effectiveness ratio of universal screening compared with elective intervention, high risk intervention, and selective screening programs were estimated US$180, US$147, and US$481, respectively[73]. Preventive strategies aimed at GSD screening incur both substantial medical budgetary savings and highly cost-effective clinical care.

METHODOLOGICAL CONSIDERATION

Since GSD has a more complicated clinical aspect, it is not the rule for people with GSD definitely to progress towards more serious complications. In clinic, 60% of the patients with GSD are asymptomatic throughout their life. In these people, early detection may not help them to avoid possible healthy problem. In addition, up to now, there has been no effective early treatment for GSD that could prevent the resulting cholecystectomy. What we could and we should do now for GSD patients is to find the patients more likely to have a serious outcome in the future and perform an early cholecystectomy to avoid the secondary common bile duct stone, gallstone pancreatitis and possible cancerization. That is why some asymptomatic patients are indicated for cholecystectomy. Also, some asymptomatic patients with diabetes and cardio-cerebrovascular complications should be treated by cholecystectomy in a stable condition to avoid unpredictable attack of GSD. That is currently the aim for GSD screening. Furthermore, since the natural history of GSD may be heterogeneous and more complicated, according to current knowledge, there is no relationship between the number of gallstones and cholecystectomy. We still have no clear idea about how the gallstone produces and what is the progression factors for GSD.

CONCLUSION

In conclusion, GSD is an escalating major health problem and involves constitutional and environmental factors. Considering the fact that oral bile acids could be only selected in an extremely limited patient population (symptomatic gallbladder disease patients who are unsuitable for surgery and have small, uncalcified, and cholesterol-enriched stones), the majority of patients with or without complications will need surgery. Without suitable screening programs for symptomatic GSD, treating GSD and related complications yields substantial medical care costs. Whether routine screening for GSD is worthwhile depends on whether subjects are willing to pay the ultrasonography screening costs that would reduce the risk of further cholecystectomy.

Footnotes

P- Reviewer: Du Z, Intagliata E, Jiang B, Jiang ZY S- Editor: Ji FF L- Editor: Wang TQ E- Editor: Lu YJ

References
1.  Chen JY, Hsu CT, Liu JH, Tung TH. Clinical predictors of incident gallstone disease in a Chinese population in Taipei, Taiwan. BMC Gastroenterol. 2014;14:83.  [PubMed]  [DOI]
2.  Festi D, Dormi A, Capodicasa S, Staniscia T, Attili AF, Loria P, Pazzi P, Mazzella G, Sama C, Roda E. Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project). World J Gastroenterol. 2008;14:5282-5289.  [PubMed]  [DOI]
3.  Weikert C, Weikert S, Schulze MB, Pischon T, Fritsche A, Bergmann MM, Willich SN, Boeing H. Presence of gallstones or kidney stones and risk of type 2 diabetes. Am J Epidemiol. 2010;171:447-454.  [PubMed]  [DOI]
4.  Chen JY, Tsai ST, Hsu CT, Liu JH, Tung TH. Cost-benefit analysis of screening for gallstone disease among Chinese population in Taiwan. OAJoST. 2013;1:1-7.  [PubMed]  [DOI]
5.  Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Weight cycling and risk of gallstone disease in men. Arch Intern Med. 2006;166:2369-2374.  [PubMed]  [DOI]
6.  Méndez-Sánchez N, Chavez-Tapia NC, Motola-Kuba D, Sanchez-Lara K, Ponciano-Rodríguez G, Baptista H, Ramos MH, Uribe M. Metabolic syndrome as a risk factor for gallstone disease. World J Gastroenterol. 2005;11:1653-1657.  [PubMed]  [DOI]
7.  Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology. 2000;31:299-303.  [PubMed]  [DOI]
8.  Elmehdawi R, Elmajberi S, Behieh A, Elramli A. Prevalence of Gall Bladder Stones among Type 2 Diabetic Patients in Benghazi Libya: A Case-control Study. Libyan J Med. 2009;4:27-30.  [PubMed]  [DOI]
9.  Tung TH, Ho HM, Shih HC, Chou P, Liu JH, Chen VT, Chan DC, Liu CM. A population-based follow-up study on gallstone disease among type 2 diabetics in Kinmen, Taiwan. World J Gastroenterol. 2006;12:4536-4540.  [PubMed]  [DOI]
10.  Agunloye AM, Adebakin AM, Adeleye JO, Ogunseyinde AO. Ultrasound prevalence of gallstone disease in diabetic patients at Ibadan, Nigeria. Niger J Clin Pract. 2013;16:71-75.  [PubMed]  [DOI]
11.  Festi D, Reggiani ML, Attili AF, Loria P, Pazzi P, Scaioli E, Capodicasa S, Romano F, Roda E, Colecchia A. Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol. 2010;25:719-724.  [PubMed]  [DOI]
12.  Bellows CF, Berger DH, Crass RA. Management of gallstones. Am Fam Physician. 2005;72:637-642.  [PubMed]  [DOI]
13.  Vogt DP. Gallbladder disease: an update on diagnosis and treatment. Cleve Clin J Med. 2002;69:977-984.  [PubMed]  [DOI]
14.  Carroll BA. Preferred imaging techniques for the diagnosis of cholecystitis and cholelithiasis. Ann Surg. 1989;210:1-12.  [PubMed]  [DOI]
15.  Fletcher DR. Gallstones. Modern management. Aust Fam Physician. 2001;30:441-445.  [PubMed]  [DOI]
16.  Shaffer EA. Gallstone disease: Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006;20:981-996.  [PubMed]  [DOI]
17.  Santucci L, Natalini G, Sarpi L, Fiorucci S, Solinas A, Morelli A. Selective endoscopic retrograde cholangiography and preoperative bile duct stone removal in patients scheduled for laparoscopic cholecystectomy: a prospective study. Am J Gastroenterol. 1996;91:1326-1330.  [PubMed]  [DOI]
18.  Portincasa P, Ciaula AD, Bonfrate L, Wang DQ. Therapy of gallstone disease: What it was, what it is, what it will be. World J Gastrointest Pharmacol Ther. 2012;3:7-20.  [PubMed]  [DOI]
19.  Pereira SP, Veysey MJ, Kennedy C, Hussaini SH, Murphy GM, Dowling RH. Gallstone dissolution with oral bile acid therapy. Importance of pretreatment CT scanning and reasons for nonresponse. Dig Dis Sci. 1997;42:1775-1782.  [PubMed]  [DOI]
20.  Hussaini SH, Pereira SP, Murphy GM, Kennedy C, Wass JA, Besser GM, Dowling RH. Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid. Gut. 1995;36:126-132.  [PubMed]  [DOI]
21.  Liu CM, Tung TH, Chou P, Chen VT, Hsu CT, Chien WS, Lin YT, Lu HF, Shih HC, Liu JH. Clinical correlation of gallstone disease in a Chinese population in Taiwan: experience at Cheng Hsin General Hospital. World J Gastroenterol. 2006;12:1281-1286.  [PubMed]  [DOI]
22.  Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr. 2004;80:38-44.  [PubMed]  [DOI]
23.  Angelico F, Del Ben M, Barbato A, Conti R, Urbinati G. Ten-year incidence and natural history of gallstone disease in a rural population of women in central Italy. The Rome Group for the Epidemiology and Prevention of Cholelithiasis (GREPCO). Ital J Gastroenterol Hepatol. 1997;29:249-254.  [PubMed]  [DOI]
24.  Stinton LM, Myers RP, Shaffer EA. Epidemiology of gallstones. Gastroenterol Clin North Am. 2010;39:157-169, vii.  [PubMed]  [DOI]
25.  Liu CM, Hsu CT, Li CY, Chen CC, Liu ML, Liu JH. A population-based cohort study of symptomatic gallstone disease in diabetic patients. World J Gastroenterol. 2012;18:1652-1659.  [PubMed]  [DOI]
26.  Chien WH, Liu JH, Hou WY, Shen HJ, Chang1 TY, Tung TH. Clinical implications in the incidence and associated risk factors on gallstone disease among elderly type 2 diabetes in Kinmen, Taiwan. Int J Gerontol. 2014;8:95-99.  [PubMed]  [DOI]
27.  Liu CM, Tung TH, Tsai ST, Liu JH, Tsai YK, Chen VT, Tam TN, Lu HF, Wang KK, Hsu CT. Serum insulin, insulin resistance, beta-cell dysfunction, and gallstone disease among type 2 diabetics in Chinese population: a community-based study in Kinmen, Taiwan. World J Gastroenterol. 2005;11:7159-7164.  [PubMed]  [DOI]
28.  Pradhan SB, Joshi MR, Vaidya A. Prevalence of different types of gallstone in the patients with cholelithiasis at Kathmandu Medical College, Nepal. Kathmandu Univ Med J (KUMJ). 2009;7:268-271.  [PubMed]  [DOI]
29.  Acalovschi M, Buzas C, Radu C, Grigorescu M. Hepatitis C virus infection is a risk factor for gallstone disease: a prospective hospital-based study of patients with chronic viral C hepatitis. J Viral Hepat. 2009;16:860-866.  [PubMed]  [DOI]
30.  Khan HN, Harrison M, Bassett EE, Bates T. A 10-year follow-up of a longitudinal study of gallstone prevalence at necropsy in South East England. Dig Dis Sci. 2009;54:2736-2741.  [PubMed]  [DOI]
31.  Friedrich N, Völzke H, Hampe J, Lerch MM, Jørgensen T. Known risk factors do not explain disparities in gallstone prevalence between Denmark and northeast Germany. Am J Gastroenterol. 2009;104:89-95.  [PubMed]  [DOI]
32.  Walcher T, Haenle MM, Mason RA, Koenig W, Imhof A, Kratzer W. The effect of alcohol, tobacco and caffeine consumption and vegetarian diet on gallstone prevalence. Eur J Gastroenterol Hepatol. 2010;22:1345-1351.  [PubMed]  [DOI]
33.  Ruhl CE, Everhart JE. Gallstone disease is associated with increased mortality in the United States. Gastroenterology. 2011;140:508-516.  [PubMed]  [DOI]
34.  Al-Bayati S, Kodayer S. Gallstones in a group of Iraqi patients with type 2 diabetes mellitus. Saudi Med J. 2012;33:412-417.  [PubMed]  [DOI]
35.  Jiang ZY, Sheng X, Xu CY, Li WW, Chang XX, Sun LY, Yang XB, Yu LF. Gallbladder gallstone disease is associated with newly diagnosed coronary artery atherosclerotic disease: a cross-sectional study. PLoS One. 2013;8:e75400.  [PubMed]  [DOI]
36.  Yilmaz Y, Ayyildiz T, Akin H, Colak Y, Ozturk O, Senates E, Tuncer I, Dolar E. Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease. Gut Liver. 2014;8:313-317.  [PubMed]  [DOI]
37.  Shen HC, Hu YC, Chen YF, Tung TH. Prevalence and associated metabolic factors of gallstone disease in the elderly agricultural and fishing population of taiwan. Gastroenterol Res Pract. 2014;2014:876918.  [PubMed]  [DOI]
38.  Ibitoye BO, Adisa AO, Makinde ON, Ijarotimi AO. Prevalence and complications of gallstone disease among pregnant women in a Nigerian hospital. Int J Gynaecol Obstet. 2014;125:41-43.  [PubMed]  [DOI]
39.  Halldestam I, Kullman E, Borch K. Incidence of and potential risk factors for gallstone disease in a general population sample. Br J Surg. 2009;96:1315-1322.  [PubMed]  [DOI]
40.  Jonas E, Marsk R, Rasmussen F, Freedman J. Incidence of postoperative gallstone disease after antiobesity surgery: population-based study from Sweden. Surg Obes Relat Dis. 2010;6:54-58.  [PubMed]  [DOI]
41.  Heida A, Koot BG, vd Baan-Slootweg OH, Pels Rijcken TH, Seidell JC, Makkes S, Jansen PL, Benninga MA. Gallstone disease in severely obese children participating in a lifestyle intervention program: incidence and risk factors. Int J Obes (Lond). 2014;38:950-953.  [PubMed]  [DOI]
42.  Liu CM, Tung TH, Liu JH, Lee WL, Chou P. A community-based epidemiologic study on gallstone disease among type 2 diabetics in Kinmen, Taiwan. Dig Dis. 2004;22:87-91.  [PubMed]  [DOI]
43.  Pagliarulo M, Fornari F, Fraquelli M, Zoli M, Giangregorio F, Grigolon A, Peracchi M, Conte D. Gallstone disease and related risk factors in a large cohort of diabetic patients. Dig Liver Dis. 2004;36:130-134.  [PubMed]  [DOI]
44.  Chapman BA, Wilson IR, Frampton CM, Chisholm RJ, Stewart NR, Eagar GM, Allan RB. Prevalence of gallbladder disease in diabetes mellitus. Dig Dis Sci. 1996;41:2222-2228.  [PubMed]  [DOI]
45.  Hou WY, Tung TH, Shen HJ, Chang TY, Pesus Chou P, Liu JH. Community-based epidemiologic study on gallstone disease among elderly patients with type 2 diabetes in Kinmen, Taiwan. Int J Gerontol. 2012;6:38-41.  [PubMed]  [DOI]
46.  Senadrin MS, Gonzales RR, Gallardo L, Magboo-Gaviola MLC, Carpio RE, Lansang S. Risk factors to gallstone formation among NIDDM patients: Santo Tomas University Hospital experience. Philipp J Intern Med. 1998;36:91-94 Available from: http://www.herdin.ph/index.php/component/herdin/?view=research&cid=31345.  [PubMed]  [DOI]
47.  Sasazuki S, Kono S, Todoroki I, Honjo S, Sakurai Y, Wakabayashi K, Nishiwaki M, Hamada H, Nishikawa H, Koga H. Impaired glucose tolerance, diabetes mellitus, and gallstone disease: an extended study of male self-defense officials in Japan. Eur J Epidemiol. 1999;15:245-251.  [PubMed]  [DOI]
48.  Niemi M, Kervinen K, Rantala A, Kauma H, Päivänsalo M, Savolainen MJ, Lilja M, Kesäniemi YA. The role of apolipoprotein E and glucose intolerance in gallstone disease in middle aged subjects. Gut. 1999;44:557-562.  [PubMed]  [DOI]
49.  B OA, J BB, B OL, T BK, K IA. Gallstone disease and type-2 diabetes mellitus-the link. J Coll Physicians Surg Pak. 2007;17:594-597.  [PubMed]  [DOI]
50.  Howard JM, Hanly AM, Keogan M, Ryan M, Reynolds JV. Percutaneous cholecystostomy--a safe option in the management of acute biliary sepsis in the elderly. Int J Surg. 2009;7:94-99.  [PubMed]  [DOI]
51.  Bergman S, Sourial N, Vedel I, Hanna WC, Fraser SA, Newman D, Bilek AJ, Galatas C, Marek JE, Monette J. Gallstone disease in the elderly: are older patients managed differently? Surg Endosc. 2011;25:55-61.  [PubMed]  [DOI]
52.  van Assen S, Nagengast FM, van Goor H, Cools BM. The treatment of gallstone disease in the elderly. Ned Tijdschr Geneeskd. 2003;147:146-150.  [PubMed]  [DOI]
53.  Sun H, Tang H, Jiang S, Zeng L, Chen EQ, Zhou TY, Wang YJ. Gender and metabolic differences of gallstone diseases. World J Gastroenterol. 2009;15:1886-1891.  [PubMed]  [DOI]
54.  Attasaranya S, Fogel EL, Lehman GA. Choledocholithiasis, ascending cholangitis, and gallstone pancreatitis. Med Clin North Am. 2008;92:925-960, x.  [PubMed]  [DOI]
55.  Sachdeva S, Khan Z, Ansari MA, Khalique N, Anees A. Lifestyle and gallstone disease: scope for primary prevention. Indian J Community Med. 2011;36:263-267.  [PubMed]  [DOI]
56.  Chen LY, Qiao QH, Zhang SC, Chen YH, Chao GQ, Fang LZ. Metabolic syndrome and gallstone disease. World J Gastroenterol. 2012;18:4215-4220.  [PubMed]  [DOI]
57.  Hsu CT, Liao Y, Liu JH, Tung TH. The clinical investigation of disparity of utility values associated with gallstone disease: a pilot study. Gastroenterol Res Pract. 2013;2013:216957.  [PubMed]  [DOI]
58.  Hsu CT, Lien SY, Jiang YD, Liu JH, Shih HC, Luo JC, Tung TH.  Screening gallstone disease by ultrasound decreases the necessity of cholecystectomy. Asia Life Sci. 2013;51-60 Available from: http://journals.uplb.edu.ph/index.php/ALS/article/view/786.  [PubMed]  [DOI]
59.  Lee SK, Kim MH. Natural history of gallstone; an important and old issue, but still debatable. J Gastroenterol Hepatol. 2010;25:651-652.  [PubMed]  [DOI]
60.  Panpimanmas S, Manmee C. Risk factors for gallstone disease in a Thai population. J Epidemiol. 2009;19:116-121.  [PubMed]  [DOI]
61.  Kallien G, Lange K, Stange EF, Scheibner J. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans. Hepatology. 1999;30:14-20.  [PubMed]  [DOI]
62.  Bodmer M, Brauchli YB, Krähenbühl S, Jick SS, Meier CR. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA. 2009;302:2001-2007.  [PubMed]  [DOI]
63.  Erichsen R, Frøslev T, Lash TL, Pedersen L, Sørensen HT. Long-term statin use and the risk of gallstone disease: A population-based case-control study. Am J Epidemiol. 2011;173:162-170.  [PubMed]  [DOI]
64.  Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQ. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology. 2008;134:2101-2110.  [PubMed]  [DOI]
65.  de Bari O, Neuschwander-Tetri BA, Liu M, Portincasa P, Wang DQ. Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. J Lipids. 2012;2012:302847.  [PubMed]  [DOI]
66.  Paumgartner G, Pauletzki J, Sackmann M. Ursodeoxycholic acid treatment of cholesterol gallstone disease. Scand J Gastroenterol Suppl. 1994;204:27-31.  [PubMed]  [DOI]
67.  Gallstones and laparoscopic cholecystectomy NIH Consens Statement. 1992;10:1-28.  [PubMed]  [DOI]
68.  Friedman GD. Natural history of asymptomatic and symptomatic gallstones. Am J Surg. 1993;165:399-404.  [PubMed]  [DOI]
69.  Cuschieri A, Croce E, Faggioni A, Jakimowicz J, Lacy A, Lezoche E, Morino M, Ribeiro VM, Toouli J, Visa J. EAES ductal stone study. Preliminary findings of multi-center prospective randomized trial comparing two-stage vs single-stage management. Surg Endosc. 1996;10:1130-1135.  [PubMed]  [DOI]
70.  Chen JY, Hsu CT, Liao Y, Liu JH, Chang NT, Shih HC, Tung TH The clinical epidemiology of assessment for willingness-to-pay values associated with gallstone disease: The experience at a teaching hospital in Taiwan Asia Life Sci. 2012;1:1-9.  [PubMed]  [DOI]
71.  Kim MO, Lee KS, Kim JH, Joo JS. Willingness to pay for hospice care using the contingent valuation method. Yonsei Med J. 2011;52:510-521.  [PubMed]  [DOI]
72.  Chen JY, Tsai ST, Hsu CT, Liu JH, Tung TH. Cost-benefit analysis of screening for gallstone disease among Chinese population in Taiwan. OAJoST. 2013;1:1-7.  [PubMed]  [DOI]
73.  Puschel K, Sullivan S, Montero J, Thompson B, Díaz A. Cost-effectiveness analysis of a preventive program for gallbladder disease in Chile. Rev Med Chil. 2002;130:447-459.  [PubMed]  [DOI]